Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Patients must have met the inclusion criteria for Study 1008-157, have received double-blind study medication, and wish to receive open-label pregabalin

• Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial seizures during the 6 weeks prior to screening

• Be currently taking 1 to 3 AEDs.

Exclusion Criteria:

• Have a treatable cause of seizures

• Experienced a serious adverse event during Study 1008-157 which was determined to be possibly related to study medication